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ABSTRACT
Objectives: To date, there is no available test to predict the risk of intrapartum fetal compromise (IFC) during labor, either 
starting spontaneously or induced due to obstetrics indications. The aim of this study was to examine the effectiveness 
of placental growth factor (PIGF) in identifying cases that develop intrapartum fetal compromise (IFC) in term high-risk 
pregnancies induced for labor.
Material and methods: This prospective cross-sectional study was conducted on 40 IFC+ cases and 40 IFC- cases with 
high-risk term pregnancy and labor induction started in the Health Sciences University Gazi Yaşargil Training and Research 
Hospital, between January 2018 and April 2018. Comparisons were made between the groups in respect of placental growth 
factor (PIGF) levels, and obstetric and neonatal outcomes. 
Results: The PIGF level was found to be statistically significantly lower in the IFC+ cases compared to the IFC- cases. For 
a PIGF cutoff value of 32 pg/mL for the prediction of IFC+ cases, sensitivity was 74.4%, specificity 73.2%, NPV 75% and PPV 
72.5%, with a statistically significant difference determined between the groups. The IFC+ development risk increased 
7.91-fold in patients with PIGF ≤ 32 pg/mL.
Conclusions: The PIGF levels in cases of IFC+ high risk pregnancies were found to be statistically significantly lower 
than those of IFC- cases. However, further, large-scale randomized controlled research is necessary to demonstrate this 
relationship better.
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INTRODUCTION
Fetal compromise is defined as “hypoxia and acidosis” 
that develops associated with the accumulation of carbon 
dioxide together with a reduction in the amount of oxygen 
in intrauterine life [1]. Although methods such as the neo-
natal stress test (NST), electronic fetal heart rate monitoring, 
fetal movements (reduction of frequency and weakening), 
biophysical profile, fetal scalp blood gas sampling, and car-
diotocography (CTG) are used to diagnose fetal compromise 
in term pregnancies, there is no available test to predict the 
risk of intrapartum fetal compromise (IFC) during labor, 
which has either started spontaneously or been induced 
due to obstetrics indications [such as preeclampsia, fetal 
growth restriction (FGR), olighydroamniosis, post-term preg-
nancy, etc. [1, 2]. However, recent promising studies have 
suggested that some placental biomarkers may be useful in 
identifying antepartum and intrapartum fetal compromise 
[2–4]. Placental growth factor (PIGF), which is a candidate 
to be one of these placental biomarkers, has a potent an-
giogenic effect and assists in the formation of low resistant 
blood flow in the placental bed together with other para-
crine and autocrine chemicals and is primarily produced 
from the placenta [5]. This low placental blood flow in the 
placental bed plays a vital role in the formation of adequate 
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fetoplacental reserve that provides sufficient oxygen flow 
during uterine contractions in the intrapartum period [2, 5]. 
However, while it is not possible to exactly clarify the mecha-
nisms that provide this low resistant placental blood flow 
that is of vital significance to ensure the placental function, 
it has been asserted that it causes this effect by binding to 
vascular endothelial growth factor 1(VEGFR-1) receptors 
that are of vital significance in angiogenesis and vasodila-
tion [5, 6]. At the same time, it has been demonstrated to 
be at low levels in pregnant women who have FGR, gesta-
tional hypertension or are pre-eclamptic, characterized by 
the inability to provide the low resistant blood flow in the 
placental bed as a result of abnormal placentation [7–10]. 
A recent study demonstrated that the PIGF level is lower in 
term and low risk pregnancies that develop IFC [2]. PIGF was 
found to be decreased in pregnancies with pre-eclampsia 
or FGR. However, no study has been conducted concerning 
PIGF for the identification of IFC development during term 
labor in such pregnancies [7–12].
The aim of this study was to investigate the effectiveness 
of the PIGF level in determining IFC+ cases in term high-risk 
pregnancies induced for labor.
MATERIAL AND METHODS
This prospective, cross-sectional study was conducted 
between January 20, 2018 and April 20, 2018, at Health 
Sciences University Diyarbakir Gazi Yaşargil Training and 
Research Hospital, located in southeast Turkey and serving 
a large population, where approximately 25,000 babies are 
delivered annually. Approval for the study was granted by 
the Ethics Board of the same hospital (January,19, 2018;8). 
Informed consent was obtained from all the participants be-
fore initiation of the study. The manuscript was prepared in 
accordance with the STrengthening the Reporting of OBser-
vational studies in Epidemiology (STROBE) guidelines [13] 
and the principles of the Helsinki Declaration [14]. 
The study included pregnant women with a gestational 
age of 37 weeks or more. Gestational age was calculated us-
ing either the first trimester ultrasound measurements or the 
last menstrual date. Following admission to the delivery unit 
with any obstetrics indications, labor induction was started 
with 10 mg dinoprostol (Propess™, Ferring, Germany). The 
obstetrics indications defined for labor induction were 
oligohydroamniosis (amniotic fluid index < 5 cm [15]), FGR 
(estimated fetal weight < 10th percentile [2]), pre-eclampsia 
and post-term (pregnancy week ≥ 42 weeks). The cases were 
divided into two groups as 40 pregnant women who were 
admitted with the above indications, diagnosed with IFC by 
intrapartum continuous fetal monitoring during labor and 
underwent emergency cesarean section, and 40 pregnant 
women who were not diagnosed with IFC and gave birth 
vaginally. When designing the study, there were planned to 
be 40 pregnant women in each group and the study was 
stopped when the number of pregnant women reached 
40 in both groups. During intrapartum continuous fetal 
monitoring, IFC+ cases were diagnosed based on The In-
ternational Federation of Gynecology and Obstetrics (FIGO) 
2015 guidelines criteria (Baseline heart rate: < 100 beats 
per minute, Variability: Reduced variability for > 15 minute, 
increased variability for > 30 minutes or sinusoidal pattern 
for > 30 minutes, Decelerations: Repetitive late or prolonged 
deceleration for > 30 minutes or 20 minutes if reduced vari-
ability or one prolonged deceleration was > 5 minutes) [16]. 
The venous blood samples taken from all pregnant women 
during admission to the delivery unit were withdrawn into 
10 mL ethylenediaminetetraacetic acid (EDTA) plasma tubes, 
rapidly centrifuged for 20 minutes (2000–3000 rpm) and 
stored at -80˚C. In addition, the age, gravida, parity, systol-
ic-diastolic blood pressure, pregnancy week, admission indi-
cation, type of delivery, infant birth weight, 1 and 5-minute 
APGAR scores, pH value of the infant umbilical cord, ratio of 
hospitalization in the neonatal intensive care unit (NICU) and 
placental weight were recorded. Comparisons were made 
between the IFC+ and IFC- cases in respect of all the param-
eters. A cut-off point was determined for PIGF in the venous 
blood samples and the sensitivity, specificity, negative pre-
dictive value (NPV) and positive predictive value (PPV) were 
calculated for the prediction of IFC+ cases. Patients were 
excluded from the study if they were diagnosed with fetal 
anomaly, had twin pregnancies, non-vertex presentation, 
previous uterine surgery, a diagnosis of pre-gestational 
diabetes mellitus or gestational diabetes mellitus, a chronic 
disease, or contraindications for vaginal delivery.
PIGF Analysis
After reaching 40 pregnant women in both study 
groups, the venous blood samples that had been taken 
and stored at -80˚C were assayed for PIGF levels using the 
enzyme-linked immunosorbent assay (Rel Assay Diagnostics®, 
Mega Tıp, Gaziantep, Turkey) according to the manufac-
turer’s instructions. 
Statistical Analysis 
Descriptive statistics (mean, standard deviation, mini-
mum, median, maximum, interquartile range) were used 
to define continuous variables. The comparison of two in-
dependent variables not conforming to normal distribu-
tion was made using the Independent Samples t-test. The 
Chi-Square test (or, when appropriate, the Fisher Exact test 
and Mann-Whitney U test) was used to determine the rela-
tionship between categorical variables. Receiver operator 
characteristic (ROC) curve analysis was applied to deter-
mine the most compatible cut-off point for the PIGF level 
(according to the Youden Index). The specificity, sensitivity, 
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area under the ROC curve (AUC), NPV and PPV of the test in 
predicting IFC+ values were determined according to the 
PIGF cut-off point. The statistical significance between these 
values was determined with the Chi-Square test. Logistic 
regression analysis (backward condition method) was used 
to investigate the relationship between PIGF levels and IFC 
in induced high-risk term pregnancy
RESULTS
Clinical and laboratory characteristics of the 
study population
The characteristics of the cases are summarized in Table 1. 
In the comparison between the IFC+ cases and IFC- cases, 
there was no statistically significant difference in terms 
of age, gravida, parity, systolic blood pressure, diastolic 
blood pressure, pregnancy week, oligohydroamniosis, FGR, 
preeclampsia, post-term pregnancies, 1-minute APGAR 
score, 1-minute APGAR score < 7.5-minute APGAR score. 
However, there was a statistically significant difference in 
terms of infant birth weight, placenta weight, 5-minute 
APGAR score < 7 and NICU hospitalization ratio (Tab. 1).
ROC analysis
The ROC analysis was performed to determine the most 
compatible cut-off point of the PIGF level and summarized 
in Figure 1. The best cut-off point that can distinguish be-
tween the IFC- and IFC+ cases was determined as 32 pg/mL.
Table 1. Distribution of the characteristic properties of the cases
IFC+
N = 40
IFC-
N = 40 P value
Age (years), [mean ± SD] 26.15 ± 6.35 26.22 ± 6.34 0.958Ω
Gravida , [median (IQR)] 2 (2) 2 (3) 0.808£
Parity, [median (IQR)] 1 (2) 1 (3) 0.808£
Blood pressure mmHg, [mean ± SD]
- Systolic
- Diastolic 
113.25 ± 15.75
72.25 ± 10.97
109.75 ± 17.02
70.50 ± 10.85
0.343 Ω
0.475 Ω
Gestational age (wk), [mean ± SD] 39.83 ± 1.58 39.92 ± 1.37 0.763 Ω
Admission indication, (n) %
-oligohydroamnios
-post-term pregnancies
-FGR
-pre-eclampsia
13 (32.5%)
12 (30.0%)
9 (22.5%)
6 (15.0%)
17 (42.5%)
12 (30.0%)
6 (15.0%)
5 (12.5%)
0.747ψ
Type of delivery, n %
-vaginal
-emergency cesarean
40 (100.0%)
0 (0.0%)
0 (0.0%)
40 (100.0%)
---
Placental weight (g), [mean ± SD] 547.13 ± 69.87 606.25 ± 66.99 0.001 Ω
Birth weight (g), [mean ± SD] 2989.50 ± 530.06 3203.50 ± 388.72 0.043 Ω
1-minute APGAR [median (IQR) 8 (0.75) 8 (0) 0.162£
1-minute APGAR < 7, n [%] 8 (20.0%) 8 (20.0%) 1.000 ψ
5-minute APGAR [median (IQR)] 9 (0.75) 9 (0) 0.996£
5-minute APGAR < 7, n [%] 6 (15%) 0 (0.0%) 0.013 ξ
Umbilical cord pH < 7.20, n [%] 6 (15.0%) 0 (0.0%) 0.013 ξ
NICU, n [%] 8 (20.0%) 1 (2.5%) 0.014 ξ
PIGF pg/mL, [mean ± SD (median)] 23.81 ± 17.12 (17.18) 40.92 ± 13.70 (43.91) 0.001£
NICU — neonatal intensive care unit; FGR — fetal growth restriction; PIGF — Placenta growth factor; IFC — intrapartum fetal compromise; wk — week, g — gram; Ω — t 
test for independent sample;  £ — Mann-Whitney U test; ψ — Chi-Square test; ξ — Fisher-Exact test; IQR — Interquartile Range
Figure 1. ROC analysis for PIGF
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Logistic regression analysis 
The comparison of the IFC groups according to the PIGF 
classification is summarized in Table 2. Sensitivity of the test 
was determined as 74.4%, specificity as 73.2%, NPV as 75.0% 
and PPV as 72.5% in the prediction of IFC+ cases according 
to the PIGF 32 pg/mL cut-off point value, and a statistically 
significant difference was found between the two groups 
(p < 0.001). The IFC development risk increased 7.91-fold in 
patients with PIGF ≤ 32 pg/mL (Tab. 2).
DISCUSSION 
This study has shown that PIGF levels are statistically 
significantly lower in IFC+ cases compared to IFC- cases in 
induced term high-risk pregnant women. The test was found 
to have moderate-high specificity and sensitivity for the 
prediction of IFC+ cases at a cut-off value of PIGF 32 pg/mL. 
In addition, the risk of IFC development increased 7.91-fold 
in those with PIGF level ≤ 32 pg/mL. Similar to the current 
study, Bligh et al [2] determined that the PIGF levels in cases 
who developed IFC in term low-risk pregnant women were 
significantly lower than those who did not develop IFC. In 
addition, consistent with the results of the study by Bligh et 
al [2] and those of the current study, Sherrell et al [17] stated 
an association between PIGF levels and IFC.
An adequate placental reserve assists in mitigating the 
influence of short-term reduction in oxygen supply during 
contractions that occur in the intrapartum process in the 
majority of fetuses [2]. Osol et al. [5] reported that PIGF as-
sumes a vital role in ensuring the low resistance blood flow 
in the placental bed for supplying an adequate fetoplacental 
reserve. The observation of low PIGF levels in cases with de-
creased placental perfusion such as preeclampsia and FGR, 
is compatible with the results of the study by Osol et al. [5, 
9, 18–21]. The determination of low PIGF levels in pregnant 
women developing IFC in the current study may be related 
with the inability to provide the low resistance blood flow in 
the placental bed, which is of vital significance because of 
the decrease in the PIGF levels [5]. To the best of our knowl-
edge, this is the first prospective research on PIGF levels 
for the prediction of IFC in term-induced high-risk preg-
nancies. Although the prospective study by Bligh et al [2] 
was similar to the current study, they evaluated the ef-
fectiveness of PIGF levels in predicting IFC in term low-risk 
pregnancies. However, the management of term high-risk 
pregnancies is much more challenging for obstetricians and 
this highlights the significance of the current research [2].
In high-risk pregnancies such as FGR, pre-eclampsia 
and post-term pregnancy, there is no effective and reliable 
test that can be used to predict which women will develop 
IFC when labor is induced because continuation of the 
pregnancy would constitute a problem for both mother 
and infant [1, 2]. However, PIGF levels have been examined 
in order to predict this high-risk patient group in several 
studies [2, 11, 17, 22, 23]. There also are papers where the 
fetal cerebroplacental ratio (CPR) has been used to identify 
IFC in this patient group [24–27]. The purpose of all of these 
studies, similar to the current study, was to predict pregnant 
women who will develop IFC, and thereby reduce the rates 
of emergency caesarean section (CS), as there is a significant 
increase in maternal and neonatal complications follow-
ing emergency CS compared to elective CS [28, 29]. In the 
current study, the sensitivity of the test in identifying IFC+ 
cases in this patient group according to the PIGF 32 pg/ml 
cut-off point value was 74.4%. In these cases, the situation 
could be discussed with the patient before starting labor 
induction, and a planned CS could be performed if that 
decision is made, thereby reducing maternal and neonatal 
complications.
The results of the current study showed that patients 
in the IFC+ group with significantly low PIGF levels, had 
significantly lower infant birth weight and placental weight 
compared to the IFC- cases, while the 5-minute APGAR 
score < 7 rate, umbilical cord pH < 7.20 and NICU hospitaliza-
tion rate were determined to be significantly higher. These 
results are consistent with the findings of many previous 
studies which have shown an increase in adverse pregnancy 
results at low PIGF levels [9, 18–21]. However, no statistically 
significant difference was determined between the two 
groups in respect of the other parameters of age, gravida, 
parity, systolic blood pressure, diastolic blood pressure, 
pregnancy week, oligohydroamnios, FGR, pre-eclampsia, 
post-term pregnancies, 1-minute APGAR scores, 1-minute 
APGAR scores < 7, and 5-minute APGAR scores.
The limitations of the current study were that it was 
single-centered, the number of cases was low, and the 
IFC+ cases were diagnosed by continuous fetal monitor-
Table 2. Comparison of IFC groups according to PIGF classification
PIGF
IFC- IFC+ Spe. Sen. NPV PPV OR 95%CI for OR P ψ
n % n %
> 32 30 73.2 11 26.8
73.2 74.4 75.0 72.5 7.91 2.91–21.43 0.001
≤ 32 10 25.6 29 74.4
PIGF — Placenta growth factor; IFC — intrapartum fetal compromise; NPV — negative pedictive value; PPV — positive predictive value; OR — Odds Ratio 95% CI 
— 95% confidence interval; ψ — Chi-Square test
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ing during the intrapartum period according to the FIGO 
2015 guidelines, without taking fetal scalp blood samples 
from the infants and checking the fetal blood gas values. Our 
hospital serves a large population in southeast Turkey and 
there were 25,043 births in 2017. In the delivery unit, all 
pregnant women are monitored by continuous fetal moni-
toring during the intrapartum period. Fetal compromise in 
the intrapartum period is also diagnosed during continuous 
fetal monitoring according to the FIGO 2015 guidelines, and 
interventions are made. Nevertheless, the strengths of this 
study were its prospective, cross-sectional design, inclu-
sion of term-induced high-risk pregnant women, and that 
the control group was formed of similar pregnant women.
In conclusion, the PIGF levels were determined to be 
significantly lower in IFC+ cases compared to IFC- cases. With 
a cutoff value of 32 pg/mL, PlGF was determined to have 
moderate-high specificity and sensitivity for the prediction 
of IFC+ cases. However, further, large-scale randomized 
controlled research is necessary to demonstrate this rela-
tionship better.
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